Praxis Precision Medicines, Inc. (PRAX) stock
PRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$310.27−17.86 (-5.44%)
Close on Nov 16, 2026Market cap $8.66BP/E –Yield –
Praxis Precision Medicines cash
Cash and short-term investments held at the end of each period.
Praxis Precision Medicines's cash was $1.40B at Jun 30, 2026. For fiscal 2025 it was $926.10M, up 97.3% from the year before. The highest annual figure on record is $926.10M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $926.10M | +97.3% |
| FY2024 | Dec 31, 2024 | $469.50M | – |
| FY2023 | Dec 31, 2023 | $0 | -100.0% |
| FY2022 | Dec 31, 2022 | $100.91M | -63.4% |
| FY2021 | Dec 31, 2021 | $275.90M | -7.2% |
| FY2020 | Dec 31, 2020 | $297.21M | +554.4% |
| FY2019 | Dec 31, 2019 | $45.42M | +144.8% |
| FY2018 | Dec 31, 2018 | $18.55M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.40B | +213.5% |
| Q1 FY2026 | Mar 31, 2026 | $1.40B | +196.6% |
| Q4 FY2025 | Dec 31, 2025 | $926.10M | +97.3% |
| Q3 FY2025 | Sep 30, 2025 | $389.20M | -5.4% |
| Q2 FY2025 | Jun 30, 2025 | $446.60M | +3.0% |
| Q1 FY2025 | Mar 31, 2025 | $472.00M | +94.0% |
| Q4 FY2024 | Dec 31, 2024 | $469.50M | – |
| Q3 FY2024 | Sep 30, 2024 | $411.20M | +306.8% |
| Q2 FY2024 | Jun 30, 2024 | $433.80M | +249.0% |
| Q1 FY2024 | Mar 31, 2024 | $243.30M | +183.5% |
| Q4 FY2023 | Dec 31, 2023 | $0 | -100.0% |
| Q3 FY2023 | Sep 30, 2023 | $101.09M | -18.3% |
| Q2 FY2023 | Jun 30, 2023 | $124.30M | -24.8% |
| Q1 FY2023 | Mar 31, 2023 | $85.82M | -61.4% |
| Q4 FY2022 | Dec 31, 2022 | $100.91M | -63.4% |
| Q3 FY2022 | Sep 30, 2022 | $123.74M | -60.6% |
| Q2 FY2022 | Jun 30, 2022 | $165.40M | -51.2% |
| Q1 FY2022 | Mar 31, 2022 | $222.50M | -17.8% |
| Q4 FY2021 | Dec 31, 2021 | $275.90M | -7.2% |
| Q3 FY2021 | Sep 30, 2021 | $314.40M | +173.9% |
| Q2 FY2021 | Jun 30, 2021 | $339.20M | +1617.6% |
| Q1 FY2021 | Mar 31, 2021 | $270.80M | +4235.6% |
| Q4 FY2020 | Dec 31, 2020 | $297.21M | +554.4% |
| Q3 FY2020 | Sep 30, 2020 | $114.77M | +2556.8% |
| Q2 FY2020 | Jun 30, 2020 | $19.75M | +6.5% |
| Q1 FY2020 | Mar 31, 2020 | $6.25M | – |
| Q4 FY2019 | Dec 31, 2019 | $45.42M | – |
| Q3 FY2019 | Sep 30, 2019 | $4.32M | – |
| Q4 FY2018 | Dec 31, 2018 | $18.55M | – |
See a number that looks wrong?